Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Breast cancer treatment: perspectives on the oncolytic virus

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 21, 2024 4:36pm

89 Views

Post# 36234893

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virus

Cancer immunotherapy research is following a fairly typical pattern, though. Generally, drug development occurs in 10-year cycles, said Caroline Loew, formerly Bristol Myers’ R&D strategy and planning chief and now CEO of Mural Oncology., and in immunotherapy, “we’re about to see another evolution, another step change.”

“It really does start with harnessing your own immune system to fight cancer and that gives us the ability to have that durable, long-term survival impact,” said Adam Lenkowsky, Bristol Myers’ chief commercial officer.

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta